IL303741A - Antibodies against integrin alpha 11 beta 1 - Google Patents

Antibodies against integrin alpha 11 beta 1

Info

Publication number
IL303741A
IL303741A IL303741A IL30374123A IL303741A IL 303741 A IL303741 A IL 303741A IL 303741 A IL303741 A IL 303741A IL 30374123 A IL30374123 A IL 30374123A IL 303741 A IL303741 A IL 303741A
Authority
IL
Israel
Prior art keywords
antibody
seq
antigen
binding fragment
chain variable
Prior art date
Application number
IL303741A
Other languages
English (en)
Hebrew (he)
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of IL303741A publication Critical patent/IL303741A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL303741A 2020-12-18 2021-12-17 Antibodies against integrin alpha 11 beta 1 IL303741A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127849P 2020-12-18 2020-12-18
US202163213973P 2021-06-23 2021-06-23
PCT/IB2021/061926 WO2022130318A2 (en) 2020-12-18 2021-12-17 Antibodies against integrin alpha 11 beta 1

Publications (1)

Publication Number Publication Date
IL303741A true IL303741A (en) 2023-08-01

Family

ID=79021748

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303741A IL303741A (en) 2020-12-18 2021-12-17 Antibodies against integrin alpha 11 beta 1

Country Status (13)

Country Link
US (1) US20240317865A1 (https=)
EP (1) EP4263605A2 (https=)
JP (1) JP2024505790A (https=)
KR (1) KR20230121831A (https=)
AU (1) AU2021400221A1 (https=)
BR (1) BR112023011777A2 (https=)
CA (1) CA3205574A1 (https=)
CL (1) CL2023001757A1 (https=)
CO (1) CO2023008544A2 (https=)
IL (1) IL303741A (https=)
MX (1) MX2023007302A (https=)
TW (1) TW202241946A (https=)
WO (1) WO2022130318A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127500A1 (en) 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
WO2003022330A2 (en) 2001-09-12 2003-03-20 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3760722A4 (en) * 2018-03-01 2021-11-24 Hiroshima University MONOCLONAL ANTI-INTEGRIN ALPHA11 ANTIBODY AND USES THEREOF
WO2021127500A1 (en) * 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1

Also Published As

Publication number Publication date
AU2021400221A1 (en) 2023-07-13
MX2023007302A (es) 2023-09-04
US20240317865A1 (en) 2024-09-26
KR20230121831A (ko) 2023-08-21
AU2021400221A9 (en) 2025-03-13
WO2022130318A3 (en) 2022-08-04
EP4263605A2 (en) 2023-10-25
BR112023011777A2 (pt) 2023-10-03
CL2023001757A1 (es) 2024-01-05
CA3205574A1 (en) 2022-06-23
WO2022130318A2 (en) 2022-06-23
CO2023008544A2 (es) 2023-07-10
TW202241946A (zh) 2022-11-01
JP2024505790A (ja) 2024-02-08

Similar Documents

Publication Publication Date Title
US20260042845A1 (en) Antibodies against integrin alpha 11 beta 1
IL258214B (en) Anti-pd-1 antibodies and compositions
IL239674A (en) Molecules bind to the human ox40 receptor
IL255010B2 (en) Methods of increasing strength and functionality with gdf8 inhibitors
IL263223B (en) Antibodies against cd40 and their uses
IL317484A (en) Oncostatin M receptor antigen-binding proteins
IL266426A (en) Proteins bind to an antibody that opposes a leptin receptor
WO2018067819A1 (en) Compositions and methods for treatment of cancers
KR20230069961A (ko) Cd33에 대한 단일 도메인 항체
IL320488A (en) Anti-cd16a antibody and application thereof
IL303741A (en) Antibodies against integrin alpha 11 beta 1
JP2022534514A (ja) Ａｌｋ７結合タンパク質及びその使用
KR20210056325A (ko) 지질단백질 형성 감소 및 대동맥판막 경화증 및 대동맥 협착증 치료용 조성물 및 방법
US20230250182A1 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
IL296550A (en) Anti-ceramide antibodies
US20250154240A1 (en) Anti-human cxcl1 antibody
IL258242B2 (en) Preparations and methods for inhibiting cancer stem cells
EA048635B1 (ru) Антитела против интегрина альфа 11 бета 1
RU2844463C1 (ru) Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации антагониста pd-1, ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли
IL297538A (en) Anti-cd19 antibodies and uses thereof
TW202602927A (zh) 整合素α7β1抗體及其用途
CN117222666A (zh) 抗整联蛋白α11β1抗体
JP2025523477A (ja) インテグリンアルファ１１ベータ１に対する抗体及びその使用
WO2025113639A1 (zh) 抗gdf15的抗体及其方法和用途
IL323643A (en) PD-1/TIGIT binding proteins for cancer treatment